AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today reported its financial results for the first quarter ended March 31, 2006.
For the first quarter of 2006, Curis reported a net loss of $4,049,000, or ($0.08) per share, as compared to a net loss of $5,381,000 or ($0.11) per share for the same period in the prior year.
Net revenues for the first quarter of 2006 were $2,038,000 as compared to ($813,000) for the first quarter of 2005, an increase of $2,851,000. The increase in net revenues was primarily due to a decrease in contra-revenues recorded under the Company's basal cell carcinoma co-development arrangement ...
Source: HighBeam Research, Curis Reports First Quarter 2006 Financial Results.